AG
CBMG

Advisor Group’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Advisor Group’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$2K Hold
100
– – ﹤0.01% 5059
2019
Q3 		$1K Hold
100
– – ﹤0.01% 5216
2019
Q2 		$2K Hold
100
– – ﹤0.01% 5037
2019
Q1 		$2K Hold
100
– – ﹤0.01% 4998
2018
Q4 		$2K Buy
+100
New +$1.7K ﹤0.01% 4878

Other funds holding CBMG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Advisor Group's CBMG Position: Q4 2019 in Review

Advisor Group held its Cellular Biomedicine Group, Inc. (CBMG) position steady in Q4 2019 at 100 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #5059.

Advisor Group first reported a position in CBMG in Q4 2018 and has held it in 5 quarters since. 43 funds tracked by Wall St. Rank hold CBMG as of Q4 2019.

  • Advisor Group held 100 shares of Cellular Biomedicine Group, Inc. worth $2K as of Q4 2019.
  • Advisor Group left its Cellular Biomedicine Group, Inc. share count unchanged in Q4 2019.
  • Cellular Biomedicine Group, Inc. made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5059 holding.
  • Advisor Group first reported a position in Cellular Biomedicine Group, Inc. in Q4 2018 and has held it in 5 quarters since.
  • 43 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.